If the placebo group did not exist, and the investigator chose to pit the new drug only against the older, more established one, there are three possible outcomes: I. the new drug is superior to the older one in terms ofefficacy or reduced side-effects; 2. the older drug is better than the new drug; or 3. no difference between the drugs is found. If either of the first two results occur, the conclusions are relatively straightforward -the new drug should be adopted or rejected. In most of medicine, including psychiatry, though, results are rarely this clear cut. It is far more usual to find that, overall, the drugs are fairly similar, differing perhaps in terms of some ofthe side-effects (1). This puts the researcher and the consumers of the research in somewhat of a quandary, since the lack of clear-cut differences can be the result of any one of a number of reasons.
First, the drugs may actually be similar in terms of their efficacy and side-effect profiles. Another possibility, though, is that the drugs were equally ineffective in that trial. That is, although the established drug has been proven to work in other studies, the investigators may have chosen outcome measures that are relatively insensitive, or had them administered by poorly trained staff, or may not have had enough subjects in the trial to demonstrate the difference, or for anyone ofmany other reasons. For example, Peet et al (2) failed to show that either propranolol or chlorpromazine had any effect on symptoms, a result which most probably was the result of insufficient sample size (3) . Because only with the use of a placebo control group could we differentiate among these reasons, the Health Protection Branch of Health Canada and the Food and Drug Administration in the US have mandated placebo-controlled trails in testing the effectiveness of any new drug (except when the established drug can prevent death or irreversible injury). This position is reflected in most textbooks of research design (4) . 165 It may seem as if this weight ofauthority has put the matter to rest, but such is not the case. Over the years, various individuals have questioned the ethics of placebo-controlled clinical trails (5, 6) . On the one hand, ifthe new drug is proven to be effective, then patients in one group would have been kept on placebos, when effective treatments for them exist. On the other hand, if the drug is ineffective, then all patients would have been denied therapy, and half of them may have actually been put at risk for adverse side-effects. Just last year, these voices reached a crescendo in the pages of the New England Journal ofMedicine. Two leading epidemiologists, Kenneth Rothman of Boston University and editor of Epidemiology and Karen Michels of the Harvard School of Public Health (7) , argued that denying patients treatment violated the Declaration of Helsinki, which states that "every patient -including those ofa control group, if any -should be assured of the best proven diagnostic and therapeutic method." The lack of consensus within the scientific community was amply proven by the dozen or so letters to the editor in the January 5, 1995 edition ofthatjoumal, a meeting on Public Responsibility in Medicine and Psychiatry held in Boston on November 1, 1994, and a Medical Research News column in the January 6, 1995 issue of Science.
Rothman and Michels, and their supporters, maintain that large, well-designed trials would obviate the problems outlined above, and result in more ethical treatment ofpatients who are enrolled in drug trials. Others argue that there will always be less than optimal studies because of variability among researchers themselves, a lack ofmoney for very large studies, and the pressure to have drugs approved for use. Given these realities, they maintain that we cannot abandon placebo controls.
It is obvious that the place ofplacebo groups in drug trials is far from settled, and that further discussion, debate, and study are needed. In this issue, Addington (8) has written an excellent article outlining the key issues. He points out that, with placebo response rates in many trials of 25% and response rates of only 50% to standard antipsychotics, only placebo-controlled trials can reveal the effectiveness ofdrugs in treating the positive, and especially the negative, symptoms of schizophrenia. This one article will not settle the debate, and in fact, some of his conclusions may generate even more discussion. For example, he states (correctly) that most patients with schizophrenia are both voluntary and competent and, hence, can give informed consent. This begs the issue as to whether or not these subjects, or indeed any research subjects, fully comprehend "informed consent" forms and appreciate what may happen to them in the control or active treatment conditions. Also, the question of whether patients with acute schizophrenia need any medication at all is not settled in the minds of all clinicians. Be that as it may, Addington's article is a scholarly, well-reasoned contribution to the discussion, and should be read by all researchers who do trials, and all clinicians whose patients participate in them.
